Brain metastases from renal cell carcinoma treatment

• Fatal tumoral hemorrhage from brain metastases of renal cell carcinoma after stereotactic radiotherapy and immune checkpoint inhibitor and vascular endothelial growth factor-targeted therapy combinations
• Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients
• Bench-to-bedside imaging in brain metastases: a road to precision oncology
• Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival
• Special populations in metastatic renal cell carcinoma
• FDG PET/CT in the Diagnosis and After Sunitinib Follow-up of Synchronous Base of Tongue and Thyroid Metastases From Renal Cell Carcinoma
• Immunotherapy in the context of immune-specialized environment of brain metastases
• Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis

Treatment typically involves a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and supportive care aimed at managing symptoms and controlling the progression of the disease.

Clinical trials are currently investigating the role of targeted therapy and immune checkpoint inhibitor combinations in treating brain metastases and decreasing intracranial disease progression ¹⁾

Patients with brain metastases from renal cell carcinoma (RCC) may benefit from systemic combination immunotherapy as well as brain-directed local therapies, according to data presented during the 2023 ASCO Genitourinary Cancers Symposium ²⁾